Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026

The Quick Take
No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee has approved the protocol and consent documents First patient enrollment continues to be expected in the...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
GomSpace Strengthens Global Commercial Organization with Appointment of New Vice Presidents of Sales for APAC and EMEA
Appointments reinforce GomSpace's global growth strategy and strengthen regional customer engagement across Europe, the Middle East, Africa, and Asia-Pacific.…
Business
Cerillion 26.2 Expands Agentic AI and Extends Open Standards Leadership
LONDON, Nov. 4, 2026 /PRNewswire/ -- Cerillion (AIM: CER), a leading provider of composable BSS/OSS solutions to the telecoms industry, today announced the…
Business
Omnissa expands Sovereign Solution to more markets, designed to give enterprises a safe place to run AI
~Expansion of Omnissa Sovereign Solution to new global markets gives organizations greater control over where and how their digital workplace is managed~ ~A…
Business
TORM plc Q3 2026 Results, Dividend Distribution, and Financial Outlook 2026
HELLERUP, Denmark, Nov. 4, 2026 /PRNewswire/ -- "Favorable market conditions, healthy transportation demand, and strong execution contributed to a strong third…
